DT2216

DT2216 is a potent and selective degrader of BCL-XL based on PROTAC technology. DT2216 inhibits various BCL-XL-dependent leukemia and cancer cells but considerably less toxic to platelets.


Cat. No.: EX-A3965	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	885	In-stock
200mg	1450	In-stock
500mg	2250	In-stock
1g	3900	In-stock
2g	5660	In-stock
5g	9800	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


CAS No.	2365172-42-3
Purity	>98%
Formula	C77H96ClF3N10O10S4
Mol Weight	1542.355
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Khan S, Zhang X, Lv D, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25(12):1938-1947. doi:10.1038/s41591-019-0668-z [2]. He Y, Koch R, Budamagunta V, et al. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020;13(1):95. Published 2020 Jul 16. [3]. The PROTAC DT2216 Targets Cancer by Promoting BCL-XL Degradation. Cancer Discov. 2020 Feb;10(2):174. doi: 10.1158/2159-8290.CD-RW2019-185. Epub 2019 Dec 13.
CoA	CoA of DT2216

Smiles:	CC1(C)CCC(C2=CC=C(Cl)C=C2)=C(C1)CN3CCN(C4=CC=C(C(NS(=O)(C5=CC(S(C(F)(F)F)(=O)=O)=C(N[C@@H](CSC6=CC=CC=C6)CCN7CCN(C(CCCCCC(N[C@@H](C(C)(C)C)C(N8[C@@H](C[C@@H](O)C8)C(N[C@H](C9=CC=C(C%10=C(N=CS%10)C)C=C9)C)=O)=O)=O)=O)CC7)C=C5)=O)=O)C=C4)CC3


		Search